Executive Chairman Proposes Take-Private Offer; Company Reports Mixed Q4 Results, Positive 2026 Outlook, and Significant Share Repurchase

summarizeSummary

Select Medical Holdings Corporation announced a non-binding take-private offer from its Executive Chairman, reported mixed Q4 and full-year 2025 financial results with a positive 2026 outlook, and disclosed a significant share repurchase program.

check_boxKey Events

• Executive Chairman Proposes Take-Private Offer

  Robert A. Ortenzio, Executive Chairman, Co-Founder, and Director, submitted a non-binding offer to acquire all outstanding shares for cash consideration of $16.00 to $16.20 per share, creating M&A speculation and a potential price floor.

• Mixed Q4 and Full-Year 2025 Financial Results

  For Q4 2025, revenue increased 6.4% to $1,396.6 million and income from continuing operations rose 461.0% to $37.7 million, but Adjusted EBITDA decreased to $104.7 million. Full-year 2025 saw revenue up 5.1% to $5,452.8 million and income from continuing operations up 65.0% to $214.5 million, while Adjusted EBITDA declined to $493.2 million.

• Positive 2026 Business Outlook Issued

  The company provided a 2026 outlook, expecting revenue between $5.6 billion and $5.8 billion, Adjusted EBITDA between $520.0 million and $540.0 million, and fully diluted EPS between $1.22 and $1.32.

• Significant Share Repurchase Program Activity

  Select Medical repurchased 6,375,512 shares for approximately $96.5 million in 2025, representing a substantial 4.8% of the company's market capitalization, demonstrating management's confidence in the stock's value.

auto_awesomeAnalysis

This 8-K filing, released concurrently with the company's 10-K, announces several market-moving events. Most notably, it details a non-binding take-private offer from Executive Chairman Robert A. Ortenzio to acquire all outstanding shares for $16.00 to $16.20 per share, representing a slight premium to the current stock price. This proposal introduces significant M&A speculation and could establish a floor for the stock. Additionally, the company reported mixed financial results for Q4 and the full year 2025, with revenue and income from continuing operations increasing, but Adjusted EBITDA declining. However, the company issued a positive business outlook for 2026, projecting increased revenue, Adjusted EBITDA, and EPS. The filing also highlights a substantial share repurchase program, with $96.5 million (approximately 4.8% of market cap) repurchased in 2025, signaling strong management confidence in the company's valuation. A routine cash dividend was also declared. Investors should closely monitor developments regarding the take-private offer and the company's execution on its 2026 guidance.